Navigation Links
AngioGenex Reviews 2008 Achievements and Sets Goals for 2009
Date:11/25/2008

rtners and investors to support the clinical development of its drugs.

Dr. Garland set out the Company's principal goals for 2009 as follows: "We will conduct additional IND-enabling preclinical studies with AGX51 and present findings from these studies at a major cancer meeting in 2009. The new studies will include expanded safety and additional anti-tumor testing of AGX51 in animals as well as further exploration of the feasibility of use of our companion diagnostic for theranostic purposes. Our goal is to file an IND on AGX51 and to initiate human testing within the next twelve to eighteen months. AngioGenex also plans to recruit at least one new Board member who can help guide the Company's effort to raise additional capital and move its program forward. Raising capital to fund our drug development work will continue to be a central focus of effort in 2009."

Company Profile:

AngioGenex, Inc. is actively engaged in the discovery, acquisition and development of anti-cancer molecules that act by inhibiting either the Id genes or proteins to prevent the formation of new blood vessels into tumors (angiogenesis). The Company's technology is based on the research of Dr. Robert Benezra and his colleagues at the Memorial Sloan Kettering Cancer Center (MSKCC) in New York City who established that activation of the Id genes is required for the formation of new blood vessels into tumors, allowing tumors to grow and metastasize. Dr. Benezra demonstrated that the absence of the Id genes in animals results in a highly significant inhibition of tumor growth and a reduction in the size of mature tumors. The research of Dr. Benezra on the role of the Id genes in tumor formation has been widely recognized for its important therapeutic implications.

This press release may contain forward-looking statements that involve risks and uncertainties that could cause actual events or results to diffe
'/>"/>

SOURCE AngioGenex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. William Garland Joins AngioGenexs New Board of Directors
2. AngioGenex Appoints New CEO to Direct Development of Anti-Cancer Drugs
3. CBDM.T, The Market and Business Intelligence Company Reviews The Enzyme Market
4. CBDM.T, The Market and Business Intelligence Company Reviews The Biomanufacturing Market
5. Pharma Opinions Site Reviews the Breakthrough Drugs of Pharmaceutical Companies
6. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
7. Rudd Report Highlights AMDL, Inc.s Latest Business Achievements; Supports 2008 Financial Guidance
8. Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results
9. Millennium Over-Delivers on 2007 Goals and Financial Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 The report expects global cell ... 2019. It also provides a carefully analyzed data about ... for the market. , Full Copy of Report @ ... global market for cell expansion will keep witnessing growth ... this growth to be driven by rapid technological advancements, ...
(Date:12/24/2014)... 2014 China Biologic Products, Inc. (NASDAQ: ... fully integrated plasma-based biopharmaceutical company in ... subsidiary, Shandong Taibang Biological Products Co. Ltd., has ... China Food and Drug Administration (the "CFDA") for ... disclosed in the Company,s public filings, the CFDA ...
(Date:12/24/2014)... PharmaBoardroom,s new report, , ... available for free download , digs deep into this ... in the sector today. One area where ... in developing a homegrown pharmaceutical manufacturing base, even if the ... some way off. A cursory comparison with neighboring ...
(Date:12/24/2014)... 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... Clinical Trial Application (CTA) with the United ... seeking regulatory approval to initiate clinical trials for the ... Contingent on the Company receiving CTA regulatory approval, ... to assess the safety, tolerability and dose escalation of ...
Breaking Biology Technology:The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... and more. MADISON, Wis. My UW Madison ... and faculty for online organizational and scheduling tasksis migrating ... the project, Arizona-based Unicon, was also announced. , ,The ... be complete by August 2005. According to Brian Rust, ...
... Simon, left, and Charletta D. Flowers, right, who work for ... works for the Energizer Battery Company in St. Louis. ... of Milwaukee (YPM) threw an elaborate party at Milwaukee's ... ,The group had a lot to be proud of. In ...
... Islands in the Clickstream ... digital world. WTN will be reprinting excerpts from selected chapters of ... features an excerpt from chapter six, Mostly True Predictions. We hope ... A Vision of Possibilities , ,By Richard Thieme , ,It ...
Cached Biology Technology:"My UW Madison" portal migrating to uPortal 2Young Professionals of Milwaukee Celebrates Its Third Birthday, Looks To The Future 2Young Professionals of Milwaukee Celebrates Its Third Birthday, Looks To The Future 3Islands in the Clickstream: A Vision of Possibilities 2Islands in the Clickstream: A Vision of Possibilities 3Islands in the Clickstream: A Vision of Possibilities 4
(Date:12/10/2014)... N.C. , Dec. 9, 2014  Valencell, a ... it is seeing a staggering demand from its licensees ... the Company revealed, is not solely coming from fitness ... as well. "A wearable is only as ... result, accuracy is the ultimate driver in long-term mass ...
(Date:12/10/2014)... Dec. 08, 2014 Research and Markets ... of the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration ... as rural banking and upgradation of the driver,s ... in the market. Besides the aforementioned projects, biometrics ...
(Date:12/5/2014)... , Dec. 4, 2014  Tute Genomics, a ... $2.3 million in Series A1 funding led by UK-based ... also participated in the investment round. "We ... healthcare community adopts next-generation sequencing and seeks new approaches ... Reid Robison , MD MBA, and CEO of ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... a case of life imitating art, avian scents given off ... A Michigan State University researcher revealed the process of ... the current issue of Behavioral Ecology . Scents are ... attracting and evaluating mates. But this is the first study ...
... How is it that a disc-like cluster of cells transforms ... This mechanism is a mystery that man has tried ... towards understanding the issue was made nearly a century ago ... Hilde Mangold. The two used early newt embryos and identified ...
... expanded use of electronic health records (EHRs) to address ... system that can lead to readmissions and even death. ... JAMA , The Journal of the American ... using electronic health records to address patient safety issues," ...
Cached Biology News:Avian 'Axe effect' attracts attention of females and males 2Hebrew U. scientists show for first time how early human embryo acquires its shape 2E-health records should play bigger role in patient safety initiatives, researchers advocate 2
... a compact, versatile system that simultaneously harvests ... 24-well microplates into a solid filter supports ... and gamma counter. The FilterMate is ideal ... such as cell proliferation, receptor binding, nucleic ...
... base medium for preparation of minimal and synthetic ... does not contain amino acids. Both bulk and ... contains reagents to prepare 500 ml of 10X ... 10X YNB for S. cerevisiae media. Store at ...
... based screening project: , 384 ... 96 shape-diverse mixtures of 4 (5 uL each) , ... Individual compounds are dissolved in DMSO at ... Supplied in 5 96-well trays. Dilute library with ...
... Assay Kits are ideal for studying ... compounds using fluorescence polarization (FP) The ... glutathione transferase to the ligand binding ... and a proprietary, fluorescently-tagged progesterone ligand, ...
Biology Products: